Myeloma

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients live longer after cancer

The FDA is reviewing iberdomide for relapsed or refractory multiple myeloma, with a decision date set for August.

Colleen Mabasa reflected on the importance of self-advocacy, as well as seeking second opinions and ensuring patients understand all available options.

Oral KTX-1001 achieved 40% disease control in phase 1 trials, offering a new targeted therapy for aggressive t(4;14) translocation multiple myeloma.

Anxiety is not just an emotion but a presence with its own heartbeat, its own spirit, waiting in ambush for moments of vulnerability.

Quest Diagnostics debuts a new blood test for myeloma MRD, offering NGS-level sensitivity and a less invasive alternative to bone marrow biopsies.

Smoldering multiple myeloma is a complex, intermediary stage of plasma cell disorders that requires a nuanced approach to care.

The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma.

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for autologous stem cell transplant.

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

CURE sat down with Dr. Surbhi Sidana to discuss this treatment combination and what its approval by the FDA would mean for patients.

Two people have transformed my journey from pain into possibility. In their presence, I find the strength to continue. Together, they've taught me that even in collapse and ill health, life can bloom again.

In patients with relapsed/refractory multiple myeloma, Tecvayli monotherapy is associated with a 71% reduction in the risk of disease progression or death.

A stage 3 multiple myeloma diagnosis is significant, but new therapies are changing the outlook. Learn about your potential next steps.

Oya Gilbert blends hip-hop and advocacy to raise awareness about myeloma, engage patients, and address broader health issues in underserved communities.

Reach out to professionals, go to safe online sources, contact your local cancer support center. I hope these tools help you as they have helped me.

I reflect on a year of healing, family, and meaningful rituals while setting intentions for 2026 with vision, consistency and awakening.

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy played in her care.

Diagnosed with myeloma in 2017, Oya Gilbert highlights self-advocacy, emotional well-being and culturally relevant outreach for underserved patients.

Living with an incurable cancer that resists durable remission means holding hope and grief at the same time — existing between promising data and lived experience.

Oya Gilbert, diagnosed with multiple myeloma in 2017, advises patients to bring someone to appointments, ask questions and seek second opinions.

Treatment with Lynozyfic showed early responses and a manageable safety profile in patients with newly diagnosed multiple myeloma.

KLN-1010 was associated with deep, ongoing minimal residual disease (MRD)–negative responses in multiple myeloma.

Tecvayli plus Darzalex Faspro improved overall and progression-free survival versus standard daratumumab regimens in relapsed/refractory multiple myeloma.

Dr. Robert Orlowski says a single-drug option in newly diagnosed myeloma may offer strong responses with fewer side effects and preserve future treatments.